A collaboration between Denali Therapeutics Inc. and F-star Ltd. aimed at enhancing the delivery of new therapies for neurodegenerative diseases across the blood-brain barrier gained new momentum Thursday. Denali exercised an option to acquire the first target of the partnership for $24 million up front and potential milestone payments of up to $447 million, composed of preclinical, clinical, regulatory and commercial milestones.